Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein inte...
Main Authors: | Samuel Egieyeh, Elizabeth Egieyeh, Sarel Malan, Alan Christofells, Burtram Fielding |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0245258 |
Similar Items
-
Exploration of Scaffolds from Natural Products with Antiplasmodial Activities, Currently Registered Antimalarial Drugs and Public Malarial Screen Data
by: Samuel Egieyeh, et al.
Published: (2016-01-01) -
SARS-CoV-2: Virology and Drug Repurposing Approaches
by: Ratika Rahmasari, et al.
Published: (2020-07-01) -
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
by: Jiri Patocka, et al.
Published: (2021-03-01) -
Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies
by: Qazi Mohammad Sajid Jamal, et al.
Published: (2021-08-01) -
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
by: Rajaiah Alexpandi, et al.
Published: (2020-07-01)